• Treffer 1 von 3
Zurück zur Trefferliste

Possible Associations of NTRK2 Polymorphisms with Antidepressant Treatment Outcome: Findings from an Extended Tag SNP Approach

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-130924
  • Background: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to antidepressant treatment. Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398 depressed Caucasian inpatients participating in theBackground: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to antidepressant treatment. Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398 depressed Caucasian inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Two Caucasian replication samples (N = 249 and N = 247) were investigated, resulting in a total number of 894 patients. 18 tagging SNPs in the BDNF gene region and 64 tagging SNPs in the NTRK2 gene region were genotyped in the discovery sample; 16 nominally associated SNPs were tested in two replication samples. Results: In the discovery analysis, 7 BDNF SNPs and 9 NTRK2 SNPs were nominally associated with treatment response. Three NTRK2 SNPs (rs10868223, rs1659412 and rs11140778) also showed associations in at least one replication sample and in the combined sample with the same direction of effects (\(P_{corr}\) = .018, \(P_{corr}\) = .015 and \(P_{corr}\) = .004, respectively). We observed an across-gene BDNF-NTRK2 SNP interaction for rs4923468 and rs1387926. No robust interaction of associated SNPs was found in an analysis of BDNF serum protein levels as a predictor for treatment outcome in a subset of 93 patients. Conclusions/Limitations: Although not all associations in the discovery analysis could be unambiguously replicated, the findings of the present study identified single nucleotide variations in the BDNF and NTRK2 genes that might be involved in antidepressant treatment outcome and that have not been previously reported in this context. These new variants need further validation in future association studies.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Johannes M. Hennings, Martin A. Kohli, Darina Czamara, Maria Giese, Anne Eckert, Christiane Wolf, Angela Heck, Katharina Domschke, Volker Arolt, Bernhard T. Baune, Sonja Horstmann, Tanja Brückl, Torsten Klengel, Andreas Menke, Bertram Müller-Myhsok, Marcus Ising, Manfred Uhr, Susanne Lucae
URN:urn:nbn:de:bvb:20-opus-130924
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):PLoS ONE
Erscheinungsjahr:2013
Band / Jahrgang:8
Heft / Ausgabe:6
Seitenangabe:e64947
Originalveröffentlichung / Quelle:PLoS ONE 8(6): e64947. doi:10.1371/journal.pone.0064947
DOI:https://doi.org/10.1371/journal.pone.0065636
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Freie Schlagwort(e):VAL66MET polymorphism; bipolar disorder; brain; genome-wide association; major depressive disorder; messenger RNA; mood disorder; neurotrophic factor gene; sequence variations; treatment response
Datum der Freischaltung:12.05.2016
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung